IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn’s Disease: A Meta-analysis of Randomized Controlled Trials

By sjmartinez • March 13, 2025

Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S. IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials. Am J Gastroenterol. 2025 Mar 12. doi: 10.14309/ajg.0000000000003406. Epub ahead of print. PMID: 40071763.

Tags: Digestive Diseases, Publications

Vanishing Bile Duct Syndrome as a Rare Complication of Classic Hodgkin’s Lymphoma: A Case Report and Literature Review

Tai JW, Shah VD, Harmon RL, Chandna S, Yan J, Fathizadeh P, Beaven S, Karunasiri D, Kim P. Vanishing Bile Duct Syndrome as a Rare[...]

Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)

Ioannou GN, Taddei TH, Planeta BM, Huang GD, Weiss NS, Morgan TR, Dominitz JA, Abou-Alfa GK, Bashir MR, Beheshti MV, Singal AG, Moylan CA, Boland[...]

Current State Analysis of Malnutrition Screening for Ambulatory Patients With Inflammatory Bowel Disease Reveals Low Screening Rates and Telehealth as a Risk Factor

Shahrvini B, Chang A, Greb AC, Baniqued M, Prajapati DP, Harmon R, Hussani SF, Bonthala N, Syal G, Sauk JS, May FP, Limketkai BN. Current[...]